Your browser doesn't support javascript.
loading
Targeting Features of the Metabolic Syndrome Through Sympatholytic Effects of SGLT2 Inhibition.
Herat, Lakshini Y; Matthews, Jennifer; Azzam, Omar; Schlaich, Markus P; Matthews, Vance B.
Afiliação
  • Herat LY; Dobney Hypertension Centre, School of Biomedical Science - Royal Perth Hospital Unit, University of Western Australia, MRF Building, Level 3, Rear 50 Murray St, Perth, WA, 6000, Australia.
  • Matthews J; Royal Perth Hospital Research Foundation, Royal Perth Hospital, Perth, WA, Australia.
  • Azzam O; Dobney Hypertension Centre, School of Biomedical Science - Royal Perth Hospital Unit, University of Western Australia, MRF Building, Level 3, Rear 50 Murray St, Perth, WA, 6000, Australia.
  • Schlaich MP; Royal Perth Hospital Research Foundation, Royal Perth Hospital, Perth, WA, Australia.
  • Matthews VB; Dobney Hypertension Centre, School of Biomedical Science - Royal Perth Hospital Unit, University of Western Australia, MRF Building, Level 3, Rear 50 Murray St, Perth, WA, 6000, Australia.
Curr Hypertens Rep ; 24(3): 67-74, 2022 03.
Article em En | MEDLINE | ID: mdl-35235172
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Síndrome Metabólica / Diabetes Mellitus Tipo 2 / Inibidores do Transportador 2 de Sódio-Glicose / Hipertensão Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Síndrome Metabólica / Diabetes Mellitus Tipo 2 / Inibidores do Transportador 2 de Sódio-Glicose / Hipertensão Tipo de estudo: Prognostic_studies Limite: Animals / Humans Idioma: En Ano de publicação: 2022 Tipo de documento: Article